Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

Looking ahead, Sanofi has announced an ambitious share buyback program worth 5 billion euros for 2025, signaling strong confidence in its future prospects. The company projects mid to high ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris Q4: sales growth of 10.3% at CER1 and business EPS2 of €1.31 Pharma ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.